JAT is a specialist in Australia-China trade, focused on growth within the Australian health and wellness consumer goods export industry.



8 April 2022

ASX ANNOUNCEMENT

Repayment of Topwei Loan

Jatcorp Limited (ASX: JAT) is pleased to announce that the \$5 million loan from Topwei Two Pty Ltd has been repaid in full, partially from cash resources of JAT and partially from the capital raising completed this week.

JAT is in the process of undertaking a convertible note issue (subject to shareholder approval) as announced to the ASX on 31 March 2022.

JAT's cash flow is significantly enhanced as a result of the repayment of the Topwei loan. On completion of the convertible note issue, JAT will be debt free (apart from normal trade creditors).

JAT's CEO, Wilton Yao stated:

"In the last three years, JAT has moved from being a trader in third-party goods to a manufacturer of its own products. This transformation, which involved the purchase of and the subsequent upgrading of the facilities at ANMA to the highest standards, the expenditure on research to create immune support product technology and the development of its own and co-branded products, was funded in large part by the Topwei loan and other debt. Becoming clear of interest-bearing debt will enable JAT to utilise the whole of its cash flow for the manufacture and distribution of its products worldwide."

This announcement is authorised by JAT's Managing Director, Wilton Yao.

Wilton Yao Managing Director Ph: +61 3 9090 7592

About Jatcorp Limited

Jatcorp Ltd (ASX: JAT) innovates, manufactures and markets a portfolio of in-house branded FMCGs, focusing on growth opportunities in dairy products.

JAT has positioned itself as a major player in the flourishing Australian consumer goods export industry, offering Chinese retail presence, online sales to Chinese consumers through offshore platforms, and high-volume wholesaling to daigou groups and other distribution channels.